ApprovalTrail

Approval · Notice of Compliance 16094 · 2014

MYLAN-EZETIMIBE: Notice of Compliance 16094

Issued September 15, 2014

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number
16094
Date
September 15, 2014
Company
Mylan Pharmaceuticals UlcEtobicoke, Ontario, Canada
Product type
Prescription Pharmaceutical
Submission
Abbreviated New Drug Submission (ANDS)
Submission class
Other
Therapeutic class
Cholesterol absorption inhibitor
Canadian reference product
EZETROL

Products in this notice

BrandDINStatus today
MYLAN-EZETIMIBE02378035Cancelled Post Market

Medicinal ingredients